Literature DB >> 14521594

Is mild normobaric hypoxia a risk factor for venous thromboembolism?

P D Hodkinson1, B J Hunt, K Parmar, J Ernsting.   

Abstract

BACKGROUND: Modern air travel entails a cabin altitude between 1520 and 2440 m (5000-8000 ft) and thus exposure to mild hypoxia. There is debate as to whether hypoxia is causally related to venous thromboembolism (VTE) occurring during or after travel. One study suggested that a short period of hypobaric hypoxia causes activation of coagulation.
OBJECTIVES: To test the hypothesis that hypoxia alone (normobaric hypoxia) causes activation of coagulation, possibly through endothelial cell activation.
METHODS: Six healthy male volunteers were exposed for 3 h, while seated, on two separate occasions to (i) dry air (control) and (ii) hypoxic gas mixture (12.8% O2 in N2, equivalent to breathing air at 3660 m [12000 ft]).
RESULTS: There were no differences in hemostatic or endothelial markers between control and hypoxic groups, but platelet and leukocyte counts increased and were significantly higher in the hypoxic group. There were increases in fibrinogen and von Willebrand factor, as well as rheological changes, but these were not significantly different between control and hypoxic groups.
CONCLUSIONS: This small study does not support the previous suggestion that hypoxia causes activation of coagulation, and suggests that immobility-induced rheological changes may be more significant in the etiology of VTE occurring during or after travel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521594     DOI: 10.1046/j.1538-7836.2003.00407.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

Review 1.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

2.  CPU86017-RS attenuate hypoxia-induced testicular dysfunction in mice by normalizing androgen biosynthesis genes and pro-inflammatory cytokines.

Authors:  Guo-lin Zhang; Feng Yu; De-zai Dai; Yu-si Cheng; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

3.  Redox-regulation of haemostasis in hypoxic exercising humans: a randomised double-blind placebo-controlled antioxidant study.

Authors:  Lewis Fall; Julien V Brugniaux; Danielle Davis; Christopher J Marley; Bruce Davies; Karl J New; Jane McEneny; Ian S Young; Damian M Bailey
Journal:  J Physiol       Date:  2018-08-29       Impact factor: 5.182

4.  Hypoxia, such as encountered at high altitude, promotes deep vein thrombosis in mice.

Authors:  A Brill; G L Suidan; D D Wagner
Journal:  J Thromb Haemost       Date:  2013-09       Impact factor: 5.824

Review 5.  [Air travel and respiratory diseases].

Authors:  Francisco García Río; Luis Borderías Clau; Ciro Casanova Macario; Bartolomé R Celli; Joan Escarrabill Sanglás; Nicolás González Mangado; Josep Roca Torrent; Fernando Uresandi Romero
Journal:  Arch Bronconeumol       Date:  2007-02       Impact factor: 4.872

6.  Individually ventilated cages cause chronic low-grade hypoxia impacting mice hematologically and behaviorally.

Authors:  Jason M York; Allison W McDaniel; Neil A Blevins; Riley R Guillet; Sarah O Allison; Keith A Cengel; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2012-05-03       Impact factor: 7.217

7.  Influence of Acute Normobaric Hypoxia on Hemostasis in Volunteers with and without Acute Mountain Sickness.

Authors:  Marc Schaber; Veronika Leichtfried; Dietmar Fries; Maria Wille; Hannes Gatterer; Martin Faulhaber; Philipp Würtinger; Wolfgang Schobersberger
Journal:  Biomed Res Int       Date:  2015-09-15       Impact factor: 3.411

8.  Features and incidence of thromboembolic disease: A comparative study between high and low altitude dwellers in Saudi Arabia.

Authors:  Farjah H Algahtani; Fatmah S AlQahtany; Abdulrahman Al-Shehri; Abdelgalil M Abdelgader
Journal:  Saudi J Biol Sci       Date:  2020-03-12       Impact factor: 4.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.